FOCUS – US Newsletter June 2026
Focus : Behind the Scenes of the Production Ramp-Up Angelo Collot, Production & Maintenance Manager at CROSSJECT To better understand the drivers of the production ramp-up, let us begin with the men and women working on the production lines. Who are they? CROSSJECT’s production ramp-up is first and foremost built on the men and women […]
FOCUS JANUARY 2026
Design optimization to increase industrial capacity Joint interview with Didier Morin, Industrial Director, and Xavier Perin, Head of Development and Industrialization What specific challenges does the industrial manufacturing of ZENEO® present? Before addressing the challenges, it is important to highlight a key industrial advantage of ZENEO®. Our needle-free auto-injector is a common […]
EDITORIAL – Newsletter January 26
The core expertise of a specialty pharmaceutical laboratory, like that of any industrial company, lies in its ability to manage cycles. For nearly three years, the industrial scale-up cycle has been a major focus for CROSSJECT. In this edition’s Focus, Didier Morin, Industrial Director, and Xavier Perin, Head of Development and Industrialization, provide insight into […]
How does our specialty pharma operate?
Obviously, this refreshed strategy begins with ZEPIZURE®’s FDA anticipated FDA approvals, BARDA* sales and US Commercialization and continues with CJT-L15 (Hydrocortisone) and CJT-L21 (Epinephrine). From there, we are diligently work today to select and plan which products will provide our revenue growth year-after year. You are not alone in managing this process. Who else is […]
Edito CROSSJECT Newsletter – June 2025
This manufacturing marks a new strategic step in the ramp-up of our ZENEO® Factory. In fact, our extended production chain was recently modified to give CROSSJECT maximum flexibility in selecting its fill-finish subcontractors. Until now, CROSSJECT entrusted its subcontractor with both sterile pre-assembly and filling of the injector. From now on, with ZENEO® Nest, we […]
CROSSJECT News – January 2025
Today, we rely on an experienced manager accustomed to the context of smaller organizations and a Medical Director with extensive knowledge of our class of drugs. On the business development side, we are able to deal with both private and public stakeholders. Our U.S. team is, of course, supported by resources based in France, including […]
CROSSJECT’s Development in the United States
Furthermore, I firmly believe in the principle of “starting with the end in mind,” inspired by Stephen Covey’s book, “The 7 Habits of Highly Effective People”. For me, the ultimate goal is fully realized commercialization with 2 achievements —delivering ZEPIZURE® to BARDA and making the product available in pharmacies for American epilepsy patients. These milestones […]